#151434

Anti-CD44 [BU52]

Cat. #151434

Anti-CD44 [BU52]

Cat. #: 151434

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: CD44

Class: Monoclonal

Application: FACS ; IHC ; IF ; IP ; WB

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Roy Jefferis

Institute: University of Birmingham

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-CD44 [BU52]
  • Alternate name: CD44 Molecule; Hematopoietic Cell E- And L-Selectin Ligand; GP9 Lymphocyte Homing/Adhesion Receptor; Chondroitin Sulfate Proteoglycan 8; Extracellular Matrix Receptor III; Heparan Sulfate Proteoglycan; Phagocytic Glycoprotein; Hyaluronate Receptor; Hermes Antigen; ECMR-III; HUTCH-I; Epican; CDW44; MDU2; MDU3; MIC4; LHR; Cell Surface Glycoprotein CD44; Phagocytic Glycoprotein I; Soluble CD44; CSPG8; HCELL; PGP-1; MC56; Pgp1
  • Research fields: Cancer;Cell biology;Cell signaling and signal transduction;Immunology
  • Clone: BU52
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC ; IF ; IP ; WB
  • Description: A broadly distributed receptor. Variants of CD44 are associated with metastasis.
  • Immunogen: Hiatt myeloma cells
  • Isotype: IgG1
  • Myeloma used: NS0

Target Details

  • Target: CD44
  • Target background: A broadly distributed receptor. Variants of CD44 are associated with metastasis.

Applications

  • Application: FACS ; IHC ; IF ; IP ; WB

Handling

  • Format: Liquid
  • Concentration: 0.9-1.1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Knapp W. et al. 1989. Leukocyte Typing IV Oxford University Press
  • Brown et al. 2005. Exp Cell Res. 303(2):400-14. PMID: 15652352.
  • Regulation of hyaluronan binding by F-actin and colocalization of CD44 and phosphorylated ezrin/radixin/moesin (ERM) proteins in myeloid cells.
  • Takahashi et al. 2003. Lung Cancer. 41(2):145-53. PMID: 12871777.
  • Restoration of CD44S in non-small cell lung cancer cells enhanced their susceptibility to the macrophage cytotoxicity.
  • Okamoto et al. 1999. J Biol Chem. 274(36):25525-34. PMID: 10464284.
  • Regulated CD44 cleavage under the control of protein kinase C, calcium influx, and the Rho family of small G proteins.
  • Baker et al. 1998. Blood. 92(8):2830-43. PMID: 9763568.
  • Prolonged phenotypic, Fn, and molecular change in group I Burkitt lymphoma cells on short-term exposure to CD40 ligand.
  • Guo et al. 1994. Int Immunol. 6(2):213-21. PMID: 7512372.
  • Palmitoylation of CD44 interferes with CD3-mediated signaling in human T lymphocytes.
  • Lesley et al. 1993. Adv Immunol. 54:271-335. PMID: 8379464.
  • CD44 and its interaction with extracellular matrix.
  • Anstee et al. 1991. Immunology. 74(2):197-205. PMID: 1721039.
  • New monoclonal antibodies in CD44 and CD58: their use to quantify CD44 and CD58 on normal human erythrocytes and to compare the distribution of CD44 and CD58 in human tissues.